Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I , first in human ,randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of ReS19-T in healthy subjects

Next Previous
X
Search
Trial Profile

A phase I , first in human ,randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of ReS19-T in healthy subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ReS19 T (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors reMYND

    • Most Recent Events

    • 03 May 2022 Results published in the reMYND Media Release.
    • 21 Oct 2021 Results presented in the reMYND Media Release.
    • 21 Oct 2021 According to a reMYND media release, the single-ascending dose (SAD) phase completed enrollment of 58 healthy volunteers in the study and the multiple-ascending dose (MAD) phase has been initiated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top